May 16, 2023 / 02:00PM GMT
Unidentified Analyst
Welcome to the second day of the JMP Securities Life Sciences Conference. It's my pleasure to welcome ESSA Pharma, a clinical-stage pharmaceutical company focused on developing therapies for prostate cancer. Here to present for the company is CEO, David Parkinson. David?
David Parkinson - ESSA Pharma Inc. - President, CEO & Director
Brendan, thank you very much. Privileged to be here, and appreciate the invitation. So thank you all for joining. I'd like to, today, describe what we, at ESSA, are doing with respect to our unique approach to early prostate cancer.
ESSA is a company which is focused on a rather unique approach to interfering with the male hormone biology in prostate cancer. I'm here with my colleagues, Peter Virsik, our Chief Operating Officer; and David Wood, our Chief Financial Officer. Not here today is our Chief Medical Officer, who is actually working and developing a drug, if you can believe that.
So what we'll be talking about here briefly today is a unique approach to shutting down androgen-related biology
ESSA Pharma Inc at JMP Securities Life Sciences Conference Transcript
May 16, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers